Clinical Trial Update: Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating letermovir versus placebo for preventing clinically significant CMV infection in CMV-seropositive adult allogeneic hematopoietic stem c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Disease Prevention
• Cytomegalovirus Infection in Immunocompromised Patients

Drugs mentioned

• Letermovir (letermovir)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Prevention of CMV Infection or Disease | Phase 3 | Status: COMPLETED | Results posted: 2017-11-17